AAPL   365.06 (+0.26%)
FB   233.00 (-1.92%)
AMZN   2,891.50 (+0.44%)
MU   49.83 (+0.24%)
AMD   52.24 (-0.65%)
T   30.17 (+0.87%)
F   6.04 (+1.00%)
GILD   76.24 (+0.22%)
BA   180.84 (+0.29%)
AAPL   365.06 (+0.26%)
FB   233.00 (-1.92%)
AMZN   2,891.50 (+0.44%)
MU   49.83 (+0.24%)
AMD   52.24 (-0.65%)
T   30.17 (+0.87%)
F   6.04 (+1.00%)
GILD   76.24 (+0.22%)
BA   180.84 (+0.29%)
AAPL   365.06 (+0.26%)
FB   233.00 (-1.92%)
AMZN   2,891.50 (+0.44%)
MU   49.83 (+0.24%)
AMD   52.24 (-0.65%)
T   30.17 (+0.87%)
F   6.04 (+1.00%)
GILD   76.24 (+0.22%)
BA   180.84 (+0.29%)
AAPL   365.06 (+0.26%)
FB   233.00 (-1.92%)
AMZN   2,891.50 (+0.44%)
MU   49.83 (+0.24%)
AMD   52.24 (-0.65%)
T   30.17 (+0.87%)
F   6.04 (+1.00%)
GILD   76.24 (+0.22%)
BA   180.84 (+0.29%)
Log in

ASX:PARParadigm Biopharmaceuticals Stock Price, Forecast & News

A$2.41
-0.07 (-2.82 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$2.33
Now: A$2.41
A$2.45
50-Day Range
A$2.41
MA: A$2.41
A$2.48
52-Week Range
A$1.08
Now: A$2.41
A$4.50
Volume1.81 million shs
Average VolumeN/A
Market Capitalization$476.73 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable and tablet forms for the treatment of bone marrow edema, respiratory, and alphaviral arthritis diseases. The company has a strategic partnership with the Pro Players' Elite Network to identify and assist sportspeople that have existing knee and joint pathologies that would benefit from treatment with injectable Pentosan Polysulfate Sodium. Paradigm Biopharmaceuticals Limited was incorporated in 2014 and is based in Melbourne, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.60 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 9629 5566

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.78 million
Cash FlowA$0.37 per share
Book ValueA$0.40 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$476.73 million
Next Earnings DateN/A
OptionableOptionable

Receive PAR News and Ratings via Email

Sign-up to receive the latest news and ratings for PAR and its competitors with MarketBeat's FREE daily newsletter.

Paradigm Biopharmaceuticals (ASX:PAR) Frequently Asked Questions

How has Paradigm Biopharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Paradigm Biopharmaceuticals' stock was trading at A$2.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PAR shares have increased by 1.3% and is now trading at A$2.41. View which stocks have been most impacted by Coronavirus.

Has Paradigm Biopharmaceuticals been receiving favorable news coverage?

Media coverage about PAR stock has trended very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Paradigm Biopharmaceuticals earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Paradigm Biopharmaceuticals.

Who are some of Paradigm Biopharmaceuticals' key competitors?

What other stocks do shareholders of Paradigm Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Paradigm Biopharmaceuticals investors own include BHP Group (BHP), Electro Optic Systems (EOS), Envirosuite (EVS), Bubs Australia (BUB), BHP Group (BHP), Avita Medical (AVH), Afterpay Touch Group (APT), Alcidion Group (ALC), A2 Milk (A2M) and 8Common (8CO).

Who are Paradigm Biopharmaceuticals' key executives?

Paradigm Biopharmaceuticals' management team includes the following people:
  • Mr. Paul Rennie BSc, Grad Dip, MBM, MSTC, CEO, MD & Exec. Director (Age 60)
  • Mr. Kevin G. Hollingsworth, CFO & Company Sec. (Age 66)
  • Dr. Claire Kaufman, Chief Operations Officer
  • Dr. Ravi Krishnan, Chief Scientific Officer

What is Paradigm Biopharmaceuticals' stock symbol?

Paradigm Biopharmaceuticals trades on the ASX under the ticker symbol "PAR."

What is Paradigm Biopharmaceuticals' stock price today?

One share of PAR stock can currently be purchased for approximately A$2.41.

How big of a company is Paradigm Biopharmaceuticals?

Paradigm Biopharmaceuticals has a market capitalization of $476.73 million and generates $3.78 million in revenue each year.

What is Paradigm Biopharmaceuticals' official website?

The official website for Paradigm Biopharmaceuticals is www.paradigmbiopharma.com.

How can I contact Paradigm Biopharmaceuticals?

The company can be reached via phone at 61 3 9629 5566.

This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.